{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Number of participants with dose limiting toxicities which resulted in being removed from pomalidomide therapy","groups":[{"description":"Drug: pomalidomide Taken orally once a day\n\nDrug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\nDrug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\npomalidomide: Taken orally once a day\n\ndexamethasone: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\nrituximab: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15","id":"OG000","title":"Pomalidomide, Dexamethasone, Rituximab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Tolerability of Pomalidomide","type":"PRIMARY","unitOfMeasure":"participants"}